148 results about "Glutamine synthetase" patented technology

Compositions and methods for conferring herbicide resistance to and improving nitrogen utilization of bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a polypeptide that confers resistance or tolerance to herbicidal glutamine synthetase inhibitors are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated polynucleotides corresponding to herbicidal glutamine synthetase inhibitor-resistant polynucleotides are provided. Additionally, polypeptides corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated polynucleotides comprising a variant of SEQ ID NO:1, wherein the variant polynucleotide encodes a polypeptide that is resistant to inhibition by herbicidal glutamine synthetase inhibitor.

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

The present invention relates to novel therapeutic uses of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof. Furthermore, the present invention relates to the use of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof, in obtaining methods of screening and of developing drugs. Finally, the present invention relates to the novel therapeutic use of other glutamine synthetase (GS) ligands and to the use of these ligands in obtaining methods for screening and developing drugs.

The invention relates to an escherichia coli genetically engineered bacterium and a method for efficiently producing L-tryptophan by utilizing the escherichia coli genetically engineered bacterium. The genetically engineered bacterium is obtained by correspondingly transforming and combining L-tryptophan synthesis-related genes in escherichia coli through a metabolic engineering method (includinggene integration, point mutation and promoter substitution) and introducing a glutamine synthetase coding gene glnA from lactobacillus acidophilus on genome of the escherichia coli. The strain is usedfor carrying out shake-flask fermentation; 10 to 12g/L of L-tryptophan can be accumulated within 24 hours, reaches the maximum value reported in China and is improved by 15.1 percent compared with that of an existing L-tryptophan industrial strain carrying plasmid, which shows that the strain has good potential for industrially producing the L-tryptophan.

The invention provides a corynebacterium glutamicum genetically engineered bacterium over-expressing heterogenous glutamine synthetase and a construction method thereof. The construction method comprises the following steps: synthesizing and optimizing a glutamine synthetase glnA derived from lactobacillus acidophilus; by virtue of a restriction enzyme ligation method, connecting the gene glnA onto an escherichia coli-corynebacterium glutamicum shuttle type expression carrier pXMJ19, so that an expression carrier pXMJ19glnA is constructed; and introducing the expression carrier pXMJ19glnA intoa corynebacterium glutamicum GM34 or a corynebacterium glutamicum TP607, so that a genetically engineered bacterium GM34/pXMJ19glnA or TP607/pXMJ19glnA is constructed. The genetically engineered bacterium provided by the invention has the advantages that exogenous glutamine synthetase is over-expressed, so that yield of L-glutamine is obviously improved; meanwhile, the synthetase is over-expressed in an L-tryptophan producing strain, so that yield of L-tryptophan is obviously improved.

The invention relates to application of GMFB (glia maturation factor beta) as a biomarker for early diagnosis of diabetic retinopathy and for diabetes progression, application of GMFB as a therapeutic target of diabetic retinopathy, a GMFB disrupter and application of the GMFB disrupter. Compared with the prior art, the invention proves that the GMFB content in vitreous body is significantly improved in early period of diabetes in rats of STZ-induced I type diabetes (TIDM). The invention is the first to prove that GMFB content gradually drops with the development of DR (diabetic retinopathy), therefore the GMFB is applicable to dynamic detection of DR progress; the invention is the first to prove that by interfering GMFB expression in rats of DR, visual function can be protected; and the invention is the first to prove that GMFB mediates retinopathy mechanism, including causing decrease of glutamine synthetase of Muller cell, death of ganglion cells and inducing autophagy of photoreceptor cells.

The invention relates to an ammonia diagnosing/measuring reagent box which utilizes the technique of the enzyme contrasting color method and the enzyme jointing method, and belongs to the technical field of the medicine/food/environment test. The main components of the reagent box of the invention mainly include cushion liquid, coenzyme, glutamic acid, adentosine triphosphoric acid, glyceraldehyde-3-phosphate, glutamine synthetase, glyceraldehyde-3-phosphate dehydrogenase and stabilizing agent; the reagent box generates a series of enzymic reactions through the mixing of the samples and the reagent at a certain cubage rate, and then the reactants are positioned under an ultraviolet/visible light analyzer which tests the reducing speed of the absorbency at the main wave length of 340nm, thereby measuring the concentration size of the enzyme. The invention can absolutely get needed measuring result through the ultraviolet/visible light analyzer.

The invention relates to a glutamine synthetase expression vector which can be amplified and have two expression cassettes. The main components of the glutamine synthetase expression vector include the following six parts: a first expression cassette component, a second expression cassette component, an f1 replicon, a glutamine synthetase expression cassette component, an ampicillin beta lactamase hydrolysis expression cassette component and a ColE1 replicon, wherein a strong enhancer/promotor CMV (Cytomegalovirus) and an immediate early enhancer/promotor are adopted to the first expression cassette component and the second expression cassette component; a weak promotor/enhancer SV40 is adopted to the glutamine synthetase expression cassette component, so that the expression of glutamine synthetase is reduced, and the screening of high-expression cloning is facilitated; and expression protein coding genes are respectively cloned to the expression vector through a multiple cloning site A and a multiple cloning site B. The glutamine synthetase expression vector disclosed by the invention is suitable for simultaneously expressing 1-2 proteins efficiently in mammalian cells and especially suitable for expressing antibody proteins.

Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof.

A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

The invention relates to modified CHO cells and application thereof. The modified CHO cells can realize stable and high-density growth under condition of serum-free suspension culture, and preferably,the modified CHO cells do not express functional glutamine synthetase (GS) and fucosyltransferase 8 (FUT8). The modified CHO cells are particularly applicable to high-level eukaryotic expression of recombinant proteins (especially antibodies), and thus have good application prospects in the fields of genetic engineering and protein engineering.

The invention discloses recombinant bacillus subtilis. According to the recombinant bacillus subtilis, on the basis of the recombinant bacillus subtilis BSGNK, escherichia coli glutamine synthetase (EglnA) is overexpressed so as to obtain recombinant bacteria BSGNKN; and the recombinant bacillus subtilis BSGNK takes B. subtilis 168 delta nagP delta gamP delta gamA delta nagA delta nagB delta ldh delta pta delta glck::lox72 as a host, and the recombinant expression of glms and GNA1 is controlled by promoters PxylA and P43 respectively. The invention further discloses a method for promoting thesynthesis of acetylglucosamine by overexpressing the glutamine synthetase by virtue of the recombinant bacillus subtilis. The obtained recombinant bacillus subtilis has the advantages that the extracellular accumulation efficiency of the acetylglucosamine and the conversion efficiency of a substrate can be improved, the content of the acetylglucosamine in fermentation supernate is 7.8 g/L and is increased by 23.8% compared with the content of the acetylglucosamine of control bacteria BSGNK, a foundation is laid for further metabolic engineering modification of the bacillus subtilis for production of glucosamine, and in addition, the recombinant bacillus subtilis is simple in construction method and convenient to use and has a good application prospect.

The present invention relates to a novel GS (glutamine synthetase) gene knock out transgenic HEK293 (human embryonic kidney 293) cell line and a production method of a target protein using the said transgenic HEK293 cell line. Particularly, the present inventors eliminated the expression of GS in the HEK293 cells in order to overcome a barrier of the cell line selection caused by the over-expression of GS, for producing a target protein by GS/MSX system, by which the efficiency of the cell line selection for the high production of a target protein would be increased and accordingly the protein production by the selected cell line would be increased, suggesting that the human originated transgenic HEK293 cell line could be efficiently used for the production of a target protein.

Methods for the treatment of both diseases susceptible to the inhibition of mammalian glutamine synthetase and progressive hyperammonemic encephalopathy comprising administering L-methionine S-sulfoxime at a dose not to exceed 10 mg/kg body weight are disclosed. Preferably, the dose should not exceed 8 mg/kg; more preferably, the dose should not exceed 5 mg/kg; most preferably, the dose should not exceed 2.5 mg/kg.

The invention is drawn to plant cell transformation with a nucleic acid construct comprising a prokaryotic ammonium-specific asparagine synthetase, type A, coding sequence, operably linked to a chloroplast transit peptide-encoding sequence, wherein said plant cells also contain a nucleic acid construct comprising a chloroplastic glutamine synthetase coding sequence in antisense orientation. Plant cells containing both nucleic acid constructs, and plants regenerated therefrom, exhibit improved growth characteristics.

An efficient bioherbiciding xanthomonas campestris pv. retroflexus is prepared through sampling the soil near the root of weeds such as crabgrass herb, caper euphorbia, cassia, etc and their stem andleaves, separating with NPC culture medium and chlorella pyrenoidosa and glutamine synthetase depressants, and screening the bacterial strains with high herbiciding activity and broad spectrum. Its advantage is high herbiciding effect.

The invention belongs to the technical field of bioengineering, and discloses corynebacterium glutamicum for high yield of L-glutamine as well as a construction method and an application of corynebacterium glutamicum. The activity of alpha-ketoglutarate dehydrogenase and/or glutamic acid exporter protein in cells of the corynebacterium glutamicum for highly producing L-glutamine is lost, and adenylation modification of glutamine synthetase is removed. According to the corynebacterium glutamicum for highly producing L-glutamine disclosed by the invention, L-glutamine can be accumulated in a culture medium or cells, so that the yield of L-glutamine is increased to a great extent. The experiments show that the corynebacterium glutamicum disclosed by the invention is an L-glutamine high-yieldstrain; compared with an unmodified strain, the strain has the advantages that the capacity of producing L-glutamine is enhanced, L-glutamine can be effectively accumulated, the yield of L-glutamine is increased, the conversion rate is relatively high, a foundation is laid for industrial production of L-glutamine, and the strain has a wide industrial application prospect.

The invention discloses a plant-derived glutamine synthetase mutant with glufosinate-ammonium resistance, a nucleic acid molecule and application, and relates to the technical field of gene engineering. Compared with the wild glutamine synthetase, the glutamine synthetase mutant disclosed by the invention has mutation at the nth site, wherein D, E, G, H, N, P, Q and V are formed or deleted after mutation, so that the glutamine synthetase by the mutation hasglufosinate-ammonium resistance. Thus, the glutamine synthetase mutant can be used for cultivating a new glufosinate-resistant plant variety.